Aurora Cannabis Pre-Q1 Earnings Analysis: Buy, Sell or Hold the Stock?

Key Takeaways ACB's medical cannabis sales likely rose in Germany and Australia, supported by new product launches.Regulatory disruptions in Poland and seasonal market fluctuations might have dampened ACB's Q2 revenue growth.Margins remain robust with positive EBITDA, but ACB's QoQ sales dip calls for cautious near-term outlook.Aurora Cannabis (ACB) is slated to release first-quarter fiscal 2026 results on Aug. 6, before market open. The Zacks Consensus Estimate for earnings and revenues is pegged at 18 cen ...